MedWorm: Actonel

  An in vitro Assay to Measure Targeted Drug Delivery to Bone Mineral.

Authors: Jahnke W, Henry C Targeted delivery of drugs to their site of action is a promising strategy to decrease adverse effects and enhance efficacy, but successful applications of this strategy have been scarce. Human bone is a tissue with unique properties due to its high hydroxyapatite mineral content. However, with the exception of bisphosphonates, bone mineral has not been targeted in a successful clinical application of drugs that act on bone, such as anti-resorptive or bone anabolic agents. Herein we present an NMR-based in vitro assay to measure binding affinities of small molecules to hydroxyapatite (HAP) or bone powder. Binding was shown to be specific and competitive, and the assay can be carried out in a direct binding format or in competition mode. A selection of clinica...

top  

  Effects of risedronate on osteoarthritis of the knee.

Authors: Iwamoto J, Takeda T, Sato Y, Matsumoto H The purpose of the present study was to discuss the effects of risedronate on osteoarthritis (OA) of the knee by reviewing the existing literature. The literature was searched with PubMed, with respect to prospective, double-blind, randomized placebo-controlled trials (RCTs), using the following search terms: risedronate, knee, and osteoarthritis. Two RCTs met the criteria. A RCT (n = 231) showed that risedronate treatment (15 mg/day) for 1 year improved symptoms. A larger RCT (n = 1,896) showed that risedronate treatment (5 mg/day, 15 mg/day, 35 mg/week, and 50 mg/week) for 2 years did not improve signs or symptoms, nor did it alter radiological progression. However, a subanalysis study (n = 477) revealed that patients with marked cart...

top  

  Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget’s disease of bone

In conclusion, treatment with high-dose risedronate for 8 weeks resulted in clinically significant and sustained improvement of biochemical markers of bone turnover for 48 weeks in patients with PDB, and this improvement was associated with a decrease of RI uptake by Paget’s bone lesions and with reduced pain. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-009-0152-9Authors Kousei Yoh, Sasayama Hospital, Hyogo Medical College Department of Orthopedic Surgery 75 Yamauchi-cho Sasayama 669-2337 JapanShinjiro Takata, University of Tokushima Graduate School Department of Orthopedics, Institute of Health Biosciences Tokushima JapanNoriko Yoshimura, University of Tokyo Department of Joint Disease Research, 22nd Medical and Research Center Tokyo JapanJ...

top  

  Long-Term Use of Bisphosphosphonates in Osteoporosis.

Conclusions: Bisphosphonates are popular and effective for treatment of osteoporosis. Because they accumulate in bone and provide some residual antifracture reduction when treatment is stopped, we recommend a drug holiday after 5-10 yr of bisphosphonate treatment. The duration of treatment and length of the holiday are based on fracture risk and pharmacokinetics of the bisphosphonate used. Patients at mild risk might stop treatment after 5 yr and remain off as long as bone mineral density is stable and no fractures occur. Higher risk patients should be treated for 10 yr, have a holiday of no more than a year or two, and perhaps be on a nonbisphosphonate treatment during that time. PMID: 20173017 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Meta...

top  

  Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial [Breast Cancer]

Conclusion In postmenopausal women at risk of fragility fracture who were receiving adjuvant anastrozole for EBC, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable effects in BMD during 24 months. (Source: Journal of Clinical Oncology)

top  

  ACTONEL (Risedronate Sodium) Tablet, Film Coated [Physicians Total Care, Inc.]

Updated Date: Feb 17, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

top  

  Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.

Conclusions. This economic analysis showed that risedronate is a cost-effective treatment in a population of Italian women at high risk of PMO related fractures, aged 65 years and older. Risedronate becomes dominant over generic alendronate in patients of 75 years or older and its cost-effectiveness appears even improved in patients with BMD score </=-3 or </=-3.5, with/without maternal history of fractures. Risedronate should be considered as a cost-effective option versus generic alendronate, in the Italian NHS' perspective. PMID: 20145427 [PubMed - as supplied by publisher] (Source: Aging Clinical and Experimental Research)

top  

  Treatment Options for Osteoporosis

I selected a few excerpts from a patient information review in the New York Times: What is osteoporosis Osteoporosis is defined as having a bone mineral density T score of minus 2.5 or lower. Lesser degrees of bone loss, known as osteopenia, may not benefit from drug therapy. Bisphosphonates The first drug licensed to counter osteoporosis, Fosamax, is now available generically as alendronate, which can be taken once a day or, at a higher dose, once a week. A reluctance on the part of many patients to adhere to a daily or weekly regimen led to the development of Boniva (ibandronate), administered by an intravenous injection every three months. To further simplify the frequency of administration, Reclast (zoledronic acid) was developed as a once-a-year intravenous treatment. Actonel, al...

top  

  Calcium and vitamin D supplements reduce the risk of bone fractures in everyone, young and old

(NaturalNews) In recent years, Big Pharma has produced a variety of widely hyped bisphosphonate drugs including alendronate (Fosamax), ibandronate (Boniva), risedronate (Actonel) and zoledronic acid (Reclast) that are aimed at preserving bone mass and reducing the risk of fractures. Unfortunately, as NaturalNews has reported, the more these medications are pushed on patients, the more serious side effects are being reported, from dangerous heart arrhythmias (http://www.naturalnews.com/026027_drugs_health_osteoporosis_drugs.html) to dental problems, esophageal ulcers, abdominal pain and severe damage to the jaw bone. But a new study involving almost 70,000 people from throughout the U.S. and Europe shows that nutrients -- calcium and vitamin D taken together -- offer a natural, side effect-...

top  

  ACTONEL (Risedronate Sodium) Tablet, Film Coated [Procter Gamble Pharmaceuticals, Inc.]

Updated Date: Jan 26, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

top  

  SABRE: Adding risedronate to anastrozole improved BMD in postmenopausal women with early breast cancer

(Source: HemOncToday.com)

top  

  Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis.

Conclusions: Treatments for osteoporosis with established vertebral and nonvertebral fracture efficacy reduce mortality in older, frailer individuals with osteoporosis who are at high risk of fracture. PMID: 20080842 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

top  

  Prevention of aromatase inhibitor-induced bone loss using risedronate: The SABRE Trial

Source: JCO Area: News According to research published early online in the Journal of Clinical Oncology, in post-menopausal women at risk of fragility fracture who were receiving adjuvant anastrozole for early breast cancer (EBC), the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favourable effects in bone mineral density (BMD) during 24 months.   Researchers had sought to investigate the management of bone health in women with early breast cancer, who were scheduled to receive anastrazole. The study included post-menopausal women with hormone receptor-positive EBC who were assigned to one of three strata by risk of fragility fracture:   . Patients with the highest risk (H) received anastrozole 1 mg/day plus risedr...

top  

  Update in male osteoporosis.

CONCLUSIONS: Despite significant advances, there remain a number of key unresolved issues regarding the pathogenesis and management of male osteoporosis, not the least of which is increasing public awareness of this important cause of morbidity and mortality in men. PMID: 20056806 [PubMed - in process] (Source: The Journal of Clinical Endocrinology and Metabolism)

top  

  BMD Response to Delayed-Release Risedronate 35 Mg Once-A-Week Formulation Taken With or Without Breakfast

Since their introduction, bisphosphonates (BPs) have become the first line treatment for postmenopausal osteoporosis. BPs have to be taken on an empty stomach at least 30 to 60 minutes before first food or drink. Here we present one year efficacy and safety results of a novel delayed release (DR) formulation of risedronate 35 mg once-a-week (OaW) that can be taken with or without breakfast. (Source: Journal of Clinical Densitometry)

top  

  Effect of Single Annual Infusion of Zoledronic Acid (5 Mg) on Lumbar Spine Bone Mineral Density versus Daily Oral Risedronate (5 Mg) in Subgroups of Patients Receiving Glucocorticoid Therapy

Background: Persistent use of glucocorticoid drugs is associated with bone loss and increased fracture risk. Prevention and treatment of glucocorticoid-induced osteoporosis is best established with bisphosphonates.1 This 1-year, randomized, double-blind, study evaluated the effect of a single annual i.v. infusion of zoledronic acid (ZOL 5 mg) compared to daily oral risedronate (RIS 5 mg) on lumbar spine bone mineral density (LS BMD) in different subgroups of patients receiving glucocorticoid therapy. (Source: Journal of Clinical Densitometry)

top  

  ACTONEL WITH CALCIUM (Risedronate Sodium And Calcium Carbonate) Kit [Procter Gamble Pharmaceuticals, Inc.]

Updated Date: Dec 30, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

top  

  Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice

In this study, we investigated whether administration of the third-generation bisphosphonate risedronate (RIS) is effective for treating osteopenia in OASIS−/− mice. Histological and histomorphometric analyses revealed that the trabecular bones increased dramatically in OASIS−/− mice treated with RIS, owing to the inhibition of bone resorption. Intriguingly, the abnormal expansion of the rough ER in OASIS−/− osteoblasts was improved by the treatment with RIS. Taken together, we conclude that OASIS−/− mice will be useful as new model mice for evaluating the medicinal effects of osteopenia treatments and developing new drugs for the osteopenia associated with diseases such as OI and osteoporosis. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-00...

top  

  Bone drugs may help prevent breast cancer: studies

New results from a landmark women's health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. (Source: CTV Health)

top  

  Studies: Bone Drugs May Help Prevent Breast Cancer

From Associated Press (December 10, 2009) SAN ANTONIO--New results from a landmark women's health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. Women who already were... (Source: Drugs.com - Pharma News)

top  

  Study: Bone Drugs May Prevent Breast Cancer

New results from a landmark women's health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. (Source: WDSU.com - Health)

top  

  NATION: Bone drugs may prevent breast cancer

Bone drugs may prevent breast cancer -- New results from a landmark women's health study raise the exciting possibility that bone-building drugs such as Fosamax and Actonel may help prevent breast cancer. Women who already were using these medicines when... (Source: OrlandoSentinel: Medical Research)

top  

  Osteoperosis Drugs Could Help Prevent Breast Cancer

There's new evidence that women on the bone drugs Fosamax and Actonel could be cutting their chances of getting breast cancer. Women involved in the large study who were already taking these medicines, were nearly on-third less likely to develop the... (Source: OrlandoSentinel: Medical Research)

top  

  Bone-building drugs like Fosamax and Actonel may help prevent breast cancer, studies suggest

SAN ANTONIO (AP) — New results from a large women's health study suggest that bone-building drugs such as Fosamax and Actonel might help prevent breast cancer. Women who already were taking these medicines when the study began were nearly one-third... (Source: OrlandoSentinel: Medical Research)

top  

  NICE issues second final appraisal determination on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporosis

Source: NICE Area: News After considering the feedback from consultation, the NICE Appraisal Committee has prepared a second Final Appraisal Determination (FAD) on alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women and submitted it to the Institute. The amendments made in this FAD (published originally as technology appraisal guidance 160 in October 2008) are the consequence of reconsideration by the Appraisal Committee following Her Majesty's High Court of Justice order of March 2009 (see link to NeLM report below for details of the judicial review).   This guidance relates to treatments for the primary prevention of fragility fractures in postmenopausal women who have ost...

top  

  NICE issues second final appraisal determination on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporosis

Source: NICE Area: News After considering the feedback from consultation, the NICE Appraisal Committee has prepared a second Final Appraisal Determination (FAD) on alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women and submitted it to the Institute. The amendments made in this FAD (published originally as technology appraisal guidance 161 in October 2008) are the consequence of reconsideration by the Appraisal Committee following Her Majesty's High Court of Justice order of March 2009 (see link to NeLM report below for details of the judicial review).   This guidance relates to treatments for the secondary prevention of fragility fractures in postmenopausal ...

top  

  Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity

Abstract: Bone loss and alterations in bone quality are major causes leading to bone fragility in postmenopausal women. Although bisphosphonates are well known to reduce bone turnover and prevent bone loss in postmenopausal osteoporosis, their effects on other bone properties are not fully characterized. Changes in bone mineral and matrix properties may contribute to the anti-fracture efficacy observed with bisphosphonate treatments. The aim of this work was to analyze the effect of a 1-year treatment with either alendronate or risedronate, at low and high doses, on spatially resolved bone material and compositional properties that could contribute to the fracture efficacy of these agents.Distal tibias from 30 normal beagles that had been treated daily for 1 year with oral doses of vehicle...

top  

  Morphological Assessment of Basic Multicellular Unit Resorption Parameters in Dogs Shows Additional Mechanisms of Bisphosphonate Effects on Bone

Abstract  Bisphosphonates (BPs) slow bone loss by reducing initiation of new basic multicellular units (BMUs). Whether or not BPs simply prevent osteoclasts from initiating new BMUs that resorb bone or also reduce the amount of bone they resorb at the BMU level is not clear. The goal of this study was to determine the effects of BPs on three morphological parameters of individual BMUs, resorption depth (Rs.De), area (Rs.Ar), and width (Rs.Wi). After 1 year of treatment with vehicle (VEH), alendronate (ALN; 0.10, 0.20, or 1.00 mg/kg/day), or risedronate (RIS; 0.05, 0.10, or 0.50 mg/kg/day), resorption cavity morphology was assessed in vertebral trabecular bone of beagle dogs by histology. Animals treated with ALN or RIS at the doses representing those used to ...

top  

  Review of osteoporosis pharmacotherapy for geriatric patients.

Conclusions: Evidence indicates that the osteoporosis treatments currently available in the United States are beneficial for treating osteoporosis in geriatric patients. However, data are limited for the oldest patients (>/=80 years) and those with significant comorbidities. Because of the limited availability of data for geriatric patients with significant comorbidities, the properties of the various agents, including efficacy, tolerability, and potential contraindications, should be considered carefully for each geriatric patient. PMID: 20129253 [PubMed - as supplied by publisher] (Source: The American Journal of Geriatric Pharmacotherapy)

top  

  Risedronate on 2 Consecutive Days a Month Reduced Vertebral Fracture Risk at 1Year Compared With Historical Placebo

Abstract: The use of historical controls may be a viable alternative for comparing antifracture efficacy in osteoporosis fracture endpoint trials that do not have a placebo control group. The risedronate 2 consecutive days a month (2CDM) study showed that risedronate 75mg on 2 consecutive days had similar increases in bone mineral density compared with risedronate 5mg/d. To assess the antifracture efficacy of this regimen, data collected in the 2CDM study were analyzed using historical control data matched for key clinical characteristics from 2 placebo-controlled trials. Fracture rates in historical groups were compared with those of the 2CDM study treatment groups. At 12mo, vertebral fractures occurred in 5.1% and 1.0% of the placebo and 5-mg risedronate historical patients, respectively...

top  

  The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: A 2-year trial

Conclusion: The use of AIs appears to lead to lower HSA-derived BMD and hip structural indices as compared to women on no or non-AI therapy in chemotherapy-induced postmenopausal breast cancer patients. Preventive therapy with once weekly oral risedronate maintains structural, skeletal integrity independently of the use of or type of adjuvant therapy. (Source: Bone)

top  

  Correlation Between Serum C-Terminal Cross-Linking Telopeptide of Type I Collagen and Staging of Oral Bisphosphonate-Related Osteonecrosis of the Jaws

Conclusions: BRONJ is relatively rare but has been increasingly recognized in our clinic. The usefulness of the serum CTX value as an index of risk prediction continues to be debated. Considering the staging of lesions and the number of lesions, we found a significant correlation between the disease severity and the risk assessment using serum CTX. (Source: Journal of Oral and Maxillofacial Surgery)

top  

  Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading

Abstract: The suppressive effects of bisphosphonates (BPs) on bone remodeling are clear yet there is conflicting data concerning the effects of BPs on modeling (specifically formation modeling on the periosteal surface). The normal periosteal expansion that occurs during aging has significant benefits to maintaining/improving the bones' mechanical properties and thus it is important to understand whether BPs affect this bone surface. Therefore, the purpose of this study was to determine the effects of BPs on periosteal bone formation modeling induced by ovariectomy (OVX) and mechanical loading. Six-month-old Sprague–Dawley OVX rats (n=60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis. T...

top  

  Differences between bisphosphonates in binding affinities for hydroxyapatite.

Authors: Lawson MA, Xia Z, Barnett BL, Triffitt JT, Phipps RJ, Dunford JE, Locklin RM, Ebetino FH, Russell RG Bisphosphonates (BPs) inhibit bone resorption and are widely used for the treatment of bone diseases, including osteoporosis. BPs are also being studied for their effects on hydroxyapatite (HAP)-containing biomaterials. There is a growing appreciation that there are hitherto unexpected differences among BPs in their mineral binding affinities that affect their pharmacological and biological properties. To study these differences, we have developed a method based on fast performance liquid chromatography using columns of HAP to which BPs and other phosphate-containing compounds can adsorb and be eluted by using phosphate buffer gradients at pH 6.8. The individual compounds emerg...

top  

  Prescription of anti-osteoporosis drugs during 2004–2007—a nationwide register study in Norway

Conclusion  There was an increasing prevalence and a decreasing incidence of AOD use over this limited time period. There was substantial geographical variation in the prevalence of anti-osteoporosis drugs. We also observed a high minimum refill rate. Content Type Journal ArticleCategory Pharmacoepidemiology and PrescriptionDOI 10.1007/s00228-009-0746-0Authors Helene M. Devold, Norwegian Institute of Public Health Department of Chronic Diseases P.b. 4404 Nydalen 0403 Oslo NorwayGia Man Doung, Norwegian Institute of Public Health Department of Chronic Diseases P.b. 4404 Nydalen 0403 Oslo NorwayAage Tverdal, Norwegian Institute of Public Health Department of Pharmacoepidemiology Oslo NorwayKari Furu, Norwegian Institute of Public Health Department of Pharmacoepidemiology ...

top  

  ACTONEL (Risedronate Sodium) Tablet, Film Coated [Procter Gamble Pharmaceuticals, Inc.]

Updated Date: Nov 2, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

top  

  P&G: Actonel reduced fractures

Procter & Gamble Co. said a program to promote its Actonel osteoporosis drug, which is in the process of being sold, has resulted in a reduced reimbursement rate for broken bones. (PG) (Source: bizjournals.com Health Care:Biotechnology headlines)

top  

  P&G: Actonel reduced fractures

Procter & Gamble Co. said a program to promote its Actonel osteoporosis drug, which is in the process of being sold, has resulted in a reduced reimbursement rate for broken bones. (PG) (Source: bizjournals.com Health Care:Hospitals headlines)

top  

  The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis

Conclusions: Based on "real world" data the analysis supports the first line use of risedronate for the treatment of osteoporotic women in Germany. (Source: Value in Health)

top  

  Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism

Conclusion  Bisphosphonates seem associated with an increased risk of DVT/PE. However, the association does not seem to be causal. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1091-yAuthors P. Vestergaard, Aarhus University Hospital Department of Endocrinology and Metabolism C Tage Hansens Gade 2 8000 Arhus C DenmarkK. Schwartz, University of Copenhagen Department of Oral and Maxillofacial Surgery, Institute of Odontology, Faculty of Health Sciences Norre alle 20 2200 Copenhagen N DenmarkE. M. Pinholt, University of Copenhagen Department of Oral and Maxillofacial Surgery, Institute of Odontology, Faculty of Health Sciences Norre alle 20 2200 Copenhagen N DenmarkL. Rejnmark, Aarhus University Hospital Department of Endocrinology and Metaboli...

top  

  Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: Results from quantitative computed tomography-based finite element analysis of the vertebral body

The objective of this study was to use quantitative computed tomography (CT)-based nonlinear finite element modeling to evaluate how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the biomechanical effectiveness of teriparatide. Finite element models of the L1 vertebra were created from quantitative CT scans, acquired before and after 12 months of therapy with teriparatide, from 171 patients from the OPTAMISE study. These models were subjected to uniaxial compression. Total BMD-derived bone volume fraction (BV/TVd, i.e., bone volume [BV]/total volume [TV]), estimated from quantitative CT-based volumetric BMD, vertebral stiffness, and failure load (strength) were calculated for each time measurement point. The results of this study demonst...

top  

  Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases

Conclusions: Understanding of the benefits of bisphosphonate treatment can be maximised by evaluating complementary data from RCTs and observational database studies. Fracture risk reduction with bisphosphonates is shown in RCTs and in real-world clinical settings. (Source: International Journal of Clinical Practice)

top  

  Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women

This study revealed a strong preference and convenience for monthly ibandronate over weekly risedronate in Korean postmenopausal osteoporotic women. There was no significant difference in change of bone turnover marker and safety profile between the two regimens. Content Type Journal ArticleDOI 10.1007/s00223-009-9294-yAuthors Yoon-Sok Chung, Ajou University School of Medicine Department of Endocrinology and Metabolism Suwon KoreaSung-Kil Lim, Yonsei University College of Medicine Division of Endocrinology and Metabolism, Department of Internal Medicine 134 Shinchon-dong, Seodaemun-gu Seoul 120-752 South KoreaHo-Yeon Chung, KyungHee University Division of Endocrinology and Metabolism, Department of Internal Medicine Seoul KoreaIn-Kyu Lee, Kyungpook National University School of Medi...

top  

  The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial

Conclusion  Strength/weight training exercises may prevent loss of BMD in postmenopausal BCS at risk for bone loss. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1083-yAuthors N. L. Waltman, University of Nebraska Medical Center College of Nursing Lincoln Division 1230 “O” Street, Ste. 131 Lincoln NE 685880220 USAJ. J. Twiss, University of Nebraska Medical Center College of Nursing Omaha Division Omaha NE USAC. D. Ott, University of Nebraska Medical Center College of Nursing Kearney Division Kearney NE USAG. J. Gross, University of Nebraska Medical Center College of Nursing Omaha Division Omaha NE USAA. M. Lindsey, University of Nebraska Medical Center College of Nursing Omaha NE USAT. E. Moore, University of Nebraska College of Medicine...

top  

  Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA

Conclusion  Certain patient characteristics are predictors of physicians prescribing oral bisphosphonates. However, many patients remain untreated. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1079-7Authors C. Asche, University of Utah School of Medicine Salt Lake UT USAR. Nelson, University of Utah School of Medicine Salt Lake UT USAC. McAdam-Marx, University of Utah School of Medicine Salt Lake UT USAM. Jhaveri, Sanofi-Aventis Bridgewater NJ USAX. Ye, University of Utah School of Medicine Salt Lake UT USA Journal Osteoporosis InternationalOnline ISSN 1433-2965Print ISSN 0937-941X (Source: Osteoporosis International)

top  

  Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations

Abstract: Introduction: Irradiation of normal, non-malignant bone during cancer therapy can lead to atrophy and increased risk of fracture at several skeletal sites, particularly the hip. This bone loss has been largely attributed to damaged osteoblasts. Little attention has been given to increased bone resorption as a contributor to radiation-induced osteoporosis. Our aims were to identify if radiation increases bone resorption resulting in acute bone loss and if bone loss could be prevented by administering risedronate.Methods: Twenty-week-old female C57BL/6 mice were either: not irradiated and treated with placebo (NR+PL); whole-body irradiated with 2 Gy x-rays and treated with placebo (IR+PL); or irradiated and treated with risedronate (IR+RIS; 30 μg/kg every other day). Calcein inj...

top  

  Genistein-like isoflavones suppress net bone resorption in postmenopausal women

Dietary supplements containing genistein-like isoflavones suppress net bone resorption in postmenopausal women, although effects are modest compared with estrogen or risedronate therapy, show US study findings. (Source: MedWire News - Ob/Gyn)

top  

  British doctor faces action over claims of 'ghost writing'

• Medics credited with work of firms' employees• US court documents reveal 'author' cultureDoctors have been agreeing to be named as authors on studies written by employees of the pharmaceutical industry, giving greater credibility to medical research, according to new evidence.The Guardian has learned that one of Britain's leading bone specialists is facing disciplinary action over accusations that he was involved in "ghost writing".The wider phenomenon has come to light through documents disclosed in the US courts which have revealed a culture in which doctors agree to "author" studies written by employees of drug firms. The doctors may have some input but do not have access to all the evidence from the drug trial on which the paper's conclusions are based, the documents showed.The G...

top  

  Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years

Conclusion: The results of this study suggest that strontium ranelate is a cost-effective strategy, in a Belgian setting, for the treatment of postmenopausal osteoporotic women aged over 75 years. (Source: Bone)

top  

  Confounder summary scores when comparing the effects of multiple drug exposures

Little information is available comparing methods to adjust for confounding when considering multiple drug exposures. We compared three analytic strategies to control for confounding based on measured variables: conventional multivariable, exposure propensity score (EPS), and disease risk score (DRS).Each method was applied to a dataset (2000-2006) recently used to examine the comparative effectiveness of four drugs. The relative effectiveness of risedronate, nasal calcitonin, and raloxifene in preventing non-vertebral fracture, were each compared to alendronate. EPSs were derived both by using multinomial logistic regression (single model EPS) and by three separate logistic regression models (separate model EPS). DRSs were derived and event rates compared using Cox proportional hazard mod...

top  

  Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection

Conclusions: The dataset obtained from the yeast screen was validated in a mammalian system, allowing the discovery of new biological processes involved in the cellular response to nitrogen-containing bisphosphonates and opening up opportunities for development of new anticancer drugs. (Source: Genome Biology)

top  

  FDA Safety Changes: Actonel, Gardasil, Myfortic

The FDA has approved safety labeling revisions for risedronate sodium tablets, human papillomavirus quadrivalent [recombinant] vaccine, and mycophenolic acid delayed-release tablets. Medscape Medical News (Source: Medscape Today Headlines)

top  

  Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

Conclusions  Differences in the baseline fracture incidence among the cohorts may reflect differences in the risk profile of patients prescribed each bisphosphonate. The reductions observed in fracture incidence over time within each cohort suggest that the effectiveness of each bisphosphonate in clinical practice has been consistent with their efficacies demonstrated in randomized controlled trials. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-1046-3Authors A. Abelson, Cleveland Clinic Mail Code A50 9500 Euclid Avenue Cleveland OH 44195 USAJ. D. Ringe, University of Cologne Medizinische Klinik IV, Klinikum Leverkusen Cologne GermanyD. T. Gold, Duke University Medical Center Durham NC USAJ. L. Lange, Procter & Gamble Mason OH USAT. Thoma...

top  

  Osteoporosis

Abstract: The fractures that result from osteoporosis are a major public health problem. The physician needs to be aware of the major risk factors for osteoporosis and refer appropriately for bone densitometry. These risk factors include prior fracture, a family history of fracture, slender habitus, early menopause, treatment with drugs known to affect bone (glucocorticoids) and diseases known to affect bone (rheumatoid arthritis). The diagnosis of osteoporosis can be made if the bone density T-score is −2.5 or below. This information can be used with other risk factors to estimate the 10-year risk of fractures. Patients at the highest risk for fracture benefit from the many licensed treatments for this common disorder. These may be given orally (alendronate, etidronate, risedronate, iba...

top  

  Ireland's Warner Chilcott buys P&G drug business for $3.1B

Warner Chilcott said Monday it bought Procter & Gamble.'s prescription drug business, including Actonel for osteoporosis, in ... (Source: USATODAY.com Health)

top  

  G.P.13.11 Oral bisphosphonates as prophylaxis of steroid-induced osteoporosis in Duchenne muscular dystrophy

Corticosteroids are the gold-standard treatment for muscle weakness in Duchenne muscular dystrophy (DMD). The commonest side effects of steroid treatment are weight gain, behavioural problems and, in the long term, reduction of bone mineral density, with vertebral fractures being reported in up to 75% of DMD boys on steroids. Vertebral fractures may be very debilitating, cause severe pain, and where ambulation is critical, precipitate loss of independent walking. Over a 2 year period in our clinic we observed at least 6 cases of symptomatic vertebral fracture. In adult patients on long-term steroid regimens, prevention of osteoporosis with concomitant oral bisphosphonates is standard practice. Use of i.v. bisphosphonates to treat symptomatic vertebral fracture in DMD has been advocated, bu...

top  

  Actonel (Risedronate Sodium) - updated on RxList

Actonel (Risedronate Sodium) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

top  

  [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009]

Authors: Dimai HP, Pietschmann P, Resch H, Preisinger E, Fahrleitner-Pammer A, Dobnig H, Klaushofer K, Osteoporosis is a systemic skeletal disease characterized by diminished bone mass and deterioration of bone microarchitecture, leading to increased fragility and subsequent increased fracture risk. Therapeutic measures therefore aim at reducing individual fracture risk. In Austria, the following drugs, all of which have been proven to reduce fracture risk, are currently registered for the treatment of postmenopausal osteoporosis: alendronate, risedronate, etidronate, ibandronate, raloxifene, teriparatide (1-34 PTH), 1-84 PTH, strontium ranelate and salmon calcitonin. Fluorides are still available, but their role in daily practice has become negligible. Currently, there is no evidence...

top  

  Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Trial): A Multicentre, Double-Blind, Double-Dummy, Randomized Controlled Trial.

Page: 521DOI: 10.1097/01.ogx.0000356937.03800.0fAuthors: Reid, David M.; Devogelaer, Jean-Pierre; Saag, Kenneth; Roux, Christian; Lau, Chak-Sing; Reginster, Jean-Yves; Papanastasiou, Philemon; Ferreira, Alberto; Hartl, Florian; Fashola, Taiwo; Mesenbrink, Peter; Sambrook, Philip N.; for the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly (HORIZON) Trial (Source: Obstetrical & Gynecological Survey)

top  

  Risedronate inhibits human osteosarcoma cell invasion

Conclusions: Given that MMP-2 and MMP-9 are instrumental in tumor cell invasion, our results suggest the risedronate could reduce osteosarcoma cell invasion. (Source: Journal of Experimental and Clinical Cancer Research)

top  

  Antiresorptive Effects of Phytoestrogen Supplements Compared to Estradiol or Risedronate in Postmenopausal Women Using 41Ca Methodology.

Conclusions: Dietary supplements containing genistein-like isoflavones demonstrated a significant but modest ability to suppress net bone resorption in post-menopausal women at the doses supplied in this study over a 50-d intervention period. PMID: 19584189 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)

top  

  Aclasta® (zoledronic acid 5mg) approved in EU to treat steroid induced osteoporosis in men and post-menopausal women

Source: Personal Communication Area: News Zoledronic acid 5mg, currently licensed for the treatment of osteoporosis, has received a new licence in the EU for the treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture.   The new indication for glucocorticoid induced osteoporosis (GIO) is based on data from a study data published in The Lancet, which found that a single intravenous (IV) dose of zoledronate was at least as effective as daily oral risedronate in maintaining lumber spinal bone mineral density (BMD) in patients on long-term oral corticosteroid therapy (see previous NeLM report linked below). (Source: NeLM - Bone Diseases)

top  

  Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.

Authors: Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J Risedronate, a nitrogen-containing bisphosphonate, is widely used in the clinical field for the treatment of osteoporosis. Risedronate is known to exert its effects through binding to hydroxyapatite in bone tissue, inhibiting osteoclastic activity, and inducing apoptosis of osteoclasts. The purpose of this study was to determine the effects of risedronate on osteoclast differentiation in vitro and on an inflammatory bone loss model in vivo. Risedronate inhibited osteoclast differentiation in co-culture of bone marrow cells (BMCs) and osteoblasts, and suppressed receptor activator of nuclear factor (NF)-kappaB ligand (RANK...

top  

  Bisphosphonate therapy

Bisphosphonates inhibit bone resorption and bone deposition, effectively decreasing bone turnover. The most common oral bisphosphonates are alendronate (Foxamax), risedronate (Actonel), and ibandronate (Boniva). Patients who have metastatic bone disease, especially related to multiple myeloma or carcinoma of the breast or prostate, may be taking intravenous bisphosphonates to relieve bone pain. Oral forms are used to manage osteoporosis and Paget's disease. The use of these medications is generally considered lifelong. Since 2003, reports have linked widening of the periodontal ligament, tooth loss, and osteonecrosis of the jaw with the use of bisphosphonates. Most of these complications develop after dental treatment, but 25% of cases are spontaneous. Before these reports appeared, many o...

top  

  Effectiveness of Bisphosphonates for the Reduction of Clinical Fractures – An Observational Study

In this study, women aged=65 years starting treatment with any of the three bisphosphonates were followed within two databases of healthcare utilization records inclusive of years 2000–2006. Fracture risk at the time of initiating a bisphosphonate was described by utilizing, up to a 5-year history period to obtain measures of co-morbidities, medication history and a FRAX® probability of fracture. To estimate the effectiveness of each bisphosphonate, a pre-post study design was used to assess if the clinical fracture incidence decreased with adherence to an individual bisphosphonate. ‘Pre’ was defined by the fracture incidence during a wash-in phase of 3 months after starting therapy and ‘post’ was defined by the fracture incidence in the subsequent 1-year follow-up on therapy. P...

top  

  Osteoporosis-Related Nonvertebral Fracture Risk Reduction vs. Hitoric Control at Two Years with Risedronate 150mg Once-A-Month

New osteoporosis therapies are evaluated in randomized placebo-controlled trials. When evaluating alternate dosing regimens of proven therapies, it may be difficult to include a placebo group for ethical or practical reasons. Non-inferiority of the 150mg once-a-month (OAM) dose of risedronate was established in an active controlled trial (vs. risedronate 5mg daily). This analysis was done to assess the anti-fracture efficacy of OAM risedronate using historical controls.Fracture data collected as treatment emergent adverse events in the active controlled study of 150mg of risedronate was analyzed using matched historical controls (HC) from previous placebo-controlled risedronate trials. Women in the OAM study were matched with placebo subjects from the Vertebral Efficacy of Risedronate Ther...

top  

  Risedronate 150mg Once a Month in the Treatment of Postmenopausal Osteoporosis: 2 Year Efficacy and Safety Data

This was a 2-year randomized, double-blind, multi-center study designed to assess the efficacy and safety of a single 150mg risedronate once-a-month oral dose compared with the 5mg daily regimen. Postmenopausal women, at least 50 years of age,=5 years since last menses and a lumbar spine T-score < −2.5 or a T-score < 2.0 with at least one prevalent vertebral fracture (T4 to L4) were enrolled in the study. Patients were randomly assigned to receive risedronate 5mg daily (n=642) or 150mg once a month (n=650) in a double-blind fashion for 2 years. Study drug was taken on an empty stomach at least 30minutes before breakfast. Change in lumbar spine (LS) bone mineral density (BMD) was the primary endpoint. BMD of the proximal femur, bone turnover markers (urine NTX and serum CTX and BAP), new ...

top  

  The Efficacy and Tolerability of a Monthly Dosing Regimen of 75mg Risedronate Dosed on 2 Consecutive Days a Month for the Treatment of Postmenopausal Women with Osteoporosis – 2 Year Study Results

Daily dosing with risedronate reduces the incidence of vertebral and nonvertebral fractures in patients with postmenopausal osteoporosis. To explore less frequent dosing options, this double-blind, randomized, active-controlled, parallel-group study evaluated the efficacy and safety of 75mg oral risedronate administered on 2 consecutive days a month (2CDM) compared to 5mg oral risedronate daily in women with postmenopausal osteoporosis.Subjects were postmenopausal, 50 years or older with a lumbar spine (LS) BMD T-score of (Source: Journal of Clinical Densitometry)

top  

  Treatment with Risendronate and its Effect on Postmenopausal Women

In conclusion, Risedronate therapy in postmenopausal women increases BMD at lumbar spine and femoral neck. Patients receiving Risedronate showed an improvement of BMD vs control untreated group. (Source: Journal of Clinical Densitometry)

top  

  The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®

Conclusions  Risedronate is a cost-effective agent for the treatment of established osteoporosis (osteoporosis and a prior fragility fracture) in women from the age of 50 years and older and above 65 years in women with osteoporosis alone. The results support the treatment recommendations in recent UK guidelines for osteoporosis. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0989-8Authors F. Borgström, Karolinska Institute Medical Management Centre Stockholm SwedenO. Ström, Karolinska Institute Medical Management Centre Stockholm SwedenJ. Coelho, I3 Innovus Klarabergsviadukten 90, Hus D 111 60 Stockholm SwedenH. Johansson, Centre for Metabolic Bone Diseases (WHO Collaborating Centre) University of Sheffield Medical School Sheff...

top  

  The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.

Conclusions: These results demonstrate that the combination treatment of ALF and RIS at their sub-therapeutic doses can improve the mechanical properties of the spine as well as the femur and ameliorate changes in Ca metabolism in an animal model of osteoporosis, suggesting that the combination treatment of ALF and RIS has a therapeutic advantage over each monotherapy for the treatment of osteoporosis. (Source: BMC Musculoskeletal Disorders)

top  

  Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis

Abstract  To estimate the cumulative randomized evidence for the overall incidence of bisphosphonates induced jaw osteonecrosis in adjuvant treatment of breast cancer. Systematic review and meta-analysis of randomized clinical trials. Trials were located through PubMed, ISI, Cochrane Library, and major cancer scientific meetings searches. We identified 15 studies reporting data on osteonecrosis of the jaw. A total of 10,694 randomized women were included, of whom 5,312 received bisphosphonates and 5,382 received either placebo or no treatment. Osteonecrosis of the jaw was a rare event, occurring in 13 (0.24%) of the 5,312 patients receiving bisphosphonates, and in one of the 5,382 patients in the control group. All the 13 events of osteonecrosis of the jaw reported among bi...

top  

  Reply to Letter to the Editor Re “Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors” by A. Luckish et al.

We agree with Yang Ye and Shen-jiang Hu that the evaluation of the effect of risedronate treatment on circulating lipoproteins would have added an interesting dimension to the present study and would have elucidated the pathophysiology for vascular action of bisphosphonates. However, our study question focused mostly on the effect of risedronate on arterial elasticity parameters, using arterial pulse-wave contour analysis . Metabolic parameters measured during the study included routine assessment of lipid profile, which didn't include the evaluation of circulating lipoproteins. Moreover, in a recently published study which assessed the effects of alendronate on lipids levels including circulating lipoproteins, no changes in apolipoprotein-A1 and apolipoprotein-B were found . In concurrenc...

top  

  Re “Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors” by A. Luckish et al.

I read with great interest the work by A. Luckish et al. “Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors” . Accumulating evidences suggest for a link between osteoporosis and cardiovascular disease. A population-based longitudinal study demonstrated that progression of atherosclerotic calcification is associated with bone loss in women during the menopause . Cardiovascular disease and osteoporotic fractures are major health problems and the primary causes of morbidity and mortality in postmenopausal women . (Source: Bone)

top  

  Risedronate on Two Consecutive Days per Month.

Page: 355DOI: 10.2165/00002512-200926040-00006Authors: Frampton, James E. (Source: Drugs & Aging)

top  

  How Does Alendronate Compare With Risedronate for Osteoporosis Prevention?

Both agents are taken once weekly, but some differences have been found in clinical trials. Medscape Pharmacists (Source: Medscape Med Students Headlines)

top  

  Risedronate on Two Consecutive Days per Month

(Source: Drugs)

top  

  Prevention and treatment of osteoporosis in women: an update

Abstract: Approximately 45% of all women will suffer at least one osteoporotic fracture during their lifetime. Until recently, 25–50% of postmenopausal women were on hormone therapy often with prevention of osteoporosis as their main motivation. Following the Women’s Health Initiative, however, the use of hormone therapy has decreased by 30–40% in several countries. Fortunately, several other options for pharmacological intervention have been demonstrated to decrease the risk of fractures in randomised studies. Anti-catabolic drugs include calcium plus vitamin D, oestrogen, raloxifene, and bisphosphonates (e.g. alendronate, etidronate, ibandronate, pamidronate risedronate and zoledronate). Anabolic drugs include parathyroid hormone (1–34) and (1–84). Finally, strontium ranelate h...

top  

  Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease

Conclusion  RCTs can be used to examine whether bisphosphonates prevent bone loss associated with intermittent GC therapy, providing metabolically active sites such as WT are employed as the primary outcome. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0960-8Authors M. H. Kriel, University of Bristol Department of Clinical Sciences at South Bristol Bristol UKJ. H. Tobias, Avon Orthopaedic Centre, Southmead Hospital Department of Academic Rheumatology Bristol BS10 5NB UKT. J. Creed, University Hospitals Bristol NHS Foundation Trust Bristol UKM. Lockett, Frenchay Hospital Department of Medicine North Bristol NHS Trust Bristol UKJ. Linehan, Royal United Hospital Department of Medicine Bath UKA. Bell, Weston-super-Mare General Hospital Weston-...

top  

  Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8

Conclusions  Men receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00520-009-0655-xAuthors Ann E. Kearns, Mayo Clinic Rochester 200 First Street, SW Rochester MN 55905 USADonald W. Northfelt, Mayo Clinic Arizona Scottsdale AZ 85259-5404 USAAmylou C. Dueck, Mayo Clinic Arizona Scottsdale AZ 85259-5404 USAPamela J. Atherton, Mayo Clinic Rochester 200 First Street, SW Rochester MN 55905 USAShaker R. Dakhil, Wichita Community Clinical Oncolo...

top  

  Clinical Investigation of C-Terminal Cross-Linking Telopeptide Test in Prevention and Management of Bisphosphonate-Associated Osteonecrosis of the Jaws

Conclusions: The CTX test is not predictive of the development of ONJ for an individual patient but does identify those in the “risk zone,” which is a value of less than 150 pg/mL to 200 pg/mL. If medically appropriate, the bisphosphonate can be ceased so that the CTX value increases to bring the patient out of the “risk zone.” (Source: Journal of Oral and Maxillofacial Surgery)

top  

  Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

The objective of this study was to compare the changes on bone mineral density, and the effects on persistence and adverse events in patients treated for postmenopausal osteoporosis with generic alendronate or with branded alendronate (Fosamax®) or branded risedronate (Actonel®) once weekly. In this retrospective patient chart analysis, we reviewed the 1-year observational treatment results for 186 women (ITT population) with postmenopausal osteoporosis. Patients from our outpatient department, who had started with once-weekly bisphosphonate therapy between 36 and at least 12 months before this chart review, were included in this comparative three-arm study according to their treatment: A, Generic Alendonate 70 mg products; B, Branded Alendronate (Fosamax®) 70 mg once...

top  

  Implant failure with bisphosphonates

Bisphosphonates inhibit bone resorption and bone deposition, with the net effect of reducing bone turnover. These agents are given intravenously (IV) during chemotherapy to manage bone pain resulting from metastatic bone disease, especially that related to multiple myeloma and breast or prostate cancer. Oral bisphosphonates are used to manage osteoporosis and Paget's disease. Once patients begin taking bisphosphonates, their use is often lifelong. The most commonly prescribed oral bisphosphonates are alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva). Reports have linked widening of the periodontal ligament, tooth loss, and osteonecrosis with the use of bisphosphonates, usually the IV forms. Because these complications have the potential to compromise the survival of os...

top  

  Evaluating the antifracture efficacy of bisphosphonates.

This article presents a comprehensive review of the key efficacy data for currently available BPs, including their nondaily regimens, to assist clinicians in assessing treatment options for NVF prevention. PMID: 19463108 [PubMed - in process] (Source: Reviews on Recent Clinical Trials)

top  

  Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study.

CONCLUSION: The present study showed differential effect of vitamin K(2) and risedronate on trabecular bone in GC-treated rats. PMID: 19430549 [PubMed - in process] (Source: Yonsei Medical Journal)

top  

  Agreements Between Some Drugmakers, Insurers Link Prescription Drug Effectiveness to Price

Some drugmakers -- encouraged by health insurers -- have begun linking the prices of their medications to the drugs' efficacy, the New York Times reports. According to some experts, the strategy could be a positive shift toward pay-for-performance care rather than fee-for-service treatment. The practice "in theory" would unify the goal of insurers, drugmakers and employers that offer worker health coverage toward improving people's health, the Times reports. According to the Times, nationalized health systems in other countries in the past few years began using pay-for-performance contracts as a method of reducing costs and promoting cost-effective treatments.The Times profiled two examples of the agreements in the U.S. In one, Procter & Gamble and Sanofi-Aventis -- which jointly market th...

top  

  Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage

The objectives of the current study were to develop a mathematical model that simulates control and 1 year experimental results following bisphosphonate treatment (alendronate or risedronate) in the canine fourth lumbar vertebral body, validate the model by comparing simulation predictions to 3 year experimental results, and then use the model to predict potential long term effects of bisphosphonates on remodeling and microdamage accumulation. To investigate the effects of bisphosphonates on bone volume and microdamage, a mechanistic biological model was modified from previous versions to simulate remodeling in a representative volume of vertebral trabecular bone in dogs treated with various doses of alendronate or risedronate, including doses equivalent to those used for treatment of post...

top  

  Zoledronic acid 'better than risedronate for treating bone loss'

Zoledronic acid is more effective than risedronate in treating bone loss that has been caused by glucocorticoids, new research published in the Lancet has suggested. (Source: Arthritis Research Campaign)

top  

  Zoledronic Acid Infusion Effective for Bone Loss Linked With Glucocorticoid Use

In a randomized trial, a single 5-mg intravenous infusion of zoledronic acid was more acceptable to patients vs 5 mg of oral risedronate daily to prevent and treat glucocorticoid-related bone loss. Medscape Medical News (Source: Medscape Internal Medicine Headlines)

top  

  Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study

Abstract: The eValuation of IBandronate Efficacy (VIBE) head-to-head database fracture study compared fracture rates between patients treated with monthly ibandronate and weekly oral bisphosphonates (BPs).This large study included women ≥45 years old, newly prescribed monthly oral ibandronate or weekly oral alendronate or risedronate, and without malignancy or Paget's disease of bone. The primary analysis included patients who were adherent to treatment during the first 90 days after the index date. The risks of hip, nonvertebral, vertebral and any clinical fracture were compared using Cox proportional hazards models and adjusted for potential confounding factors. A secondary, “intent-to-treat” analysis included all patients who received at least one BP prescription. Sensitivity an...

top  

  Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence

Abstract: Introduction: Osteoporosis and fracture risk increase exponentially in postmenopausal females. This places a significant burden in terms of morbidity, mortality and costs that are likely to increase with an ageing population. Despite this there is very limited data on pharmacological management of osteoporosis in this high risk group.Objectives of this review: To review the published literature on the clinical efficacy and safety of specific anti osteoporosis treatments in the reduction in fracture risk in females ≥75 years of age. The following major endpoints were used in this review:Search methods for identification of studies: We performed an electronic search of Medline (1970 to June 2007) and the Cochrane Library (1996 to June 2007). Our search strategy included MeSH ter...

top  

  Actonel Makers Paying Insurer to Fix Fractures

The makers of osteoporosis drug Actonel (risedronate) are testing a program to reimburse an insurer for the cost of treating non-spinal bone fractures among women who take the drug. Reuters Health Information (Source: Medscape Ob/Gyn & Women's Health Headlines)

top  

  Risedronate Recovers Bone Loss in Patients With Prostate Cancer Undergoing Androgen-deprivation Therapy

Conclusions: The results of our study have shown that oral administration of risedronate is effective for the recovery of ADT-induced bone loss in patients with PCa. (Source: Urology)

top  

  P&G enters deal to cover fractures

Procter & Gamble Co., in a move to promote is Actonel osteoporosis drug, will begin paying an Illinois insurer for broken bones. (Source: bizjournals.com Health Care:Hospitals headlines)

top  

  Aclasta(R)/Reclast(R) Better Than Risedronate For Prevention And Treatment Of Bone Loss In Patients With Steroid-induced Osteoporosis

A study published in The Lancet1 shows that a once-yearly infusion of Aclasta®/Reclast® (zoledronic acid 5 mg)* is significantly more efficacious than risedronate in preventing and treating bone loss in men and women with osteoporosis caused by glucocorticoids, often referred to as corticosteroids or steroids1. (Source: Health News from Medical News Today)

top  

  Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats

Conclusions: While risedronate sodium prevented the decrease in bone mineral density in ovariectomized rats, atorvastatin maintained mechanical characteristics of bone and also prevented the decrease in bone mineral density as risedronate sodium. (Source: Maturitas)

top  

  Health News of the Day

is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day.Zoledronic acid 5 mg IV x 1 more effective than risedronate 5 mg po qd for prevention/tx of steroid-induced osteoporosis http://is.gd/rOYzAvotermin (recombinant, active, human TGFβ3, ID) can provide accelerated and permanent improvement in skin scarring http://is.gd/rP0AThe American Board of Allergy and Immunology is on Twitter @a_iboard and Facebook http://is.gd/rP40"Urinary potassium shows if a person is hitting the salad bar on lunch breaks-- or taking a trip to Mickey D's" http://is.gd/rPPhImage source: OpenClipArt.org, public domain. (Source: Clinical Cases and Images)

top  

  Bisphosphonate Once a Year Beats Daily Pill for Steroid-Induced Bone Loss

WHEELING, W.Va. (MedPage Today) -- A single, yearly infusion of zoledronic acid (Reclast) was more effective at preventing steroid-induced osteoporosis than daily oral risedronate (Actonel), researchers found in a randomized trial. (Source: MedPage Today Endocrinology)

top  

  Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.

CONCLUSIONS: Patients receiving monthly ibandronate therapy had a significantly reduced risk of severe GI events compared with those receiving weekly BP treatment. In addition, patients receiving a weekly BP were more likely to discontinue treatment after a severe GI event. PMID: 19318598 [PubMed - in process] (Source: The Annals of Pharmacotherapy)

top  

  Prolonged osteogenesis from human mesenchymal stem cells implanted in immunodeficient mice by using coralline hydroxyapatite incorporating rhBMP2 microspheres.

In conclusion, incorporation of hMSCs into CHA with controlled delivery of BMP showed prolonged bone formation in immunodeficient mice. Further research is required to optimize the growth factor delivery system and to understand the underlying cellular and molecular mechanisms involved. (c) 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2009. PMID: 19322875 [PubMed - as supplied by publisher] (Source: Biomed Res)

top  

  Risedronate taken before breakfast 'shows better results'

Taking risedronate before breakfast increases bone mineral density more compared to taking the drug later in the day, new research published in the journal Osteoporosis International has suggested. (Source: Arthritis Research Campaign)

top  

  Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis

Conclusion  Results of these two studies demonstrate that overall flexible dosing of risedronate leads to smaller BMD gains compared to before-breakfast dosing. This result may be due to poorer adherence to the flexible dosing instructions that may be more pronounced in patients in certain geographic regions. If patients cannot abide by before-breakfast dosing and flexible dosing is an approved option, one can expect suboptimal BMD results with flexible dosing. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0893-2Authors D. L. Kendler, Osteoporosis Centre of British Columbia 600-1285 W Broadway Vancouver BC V6H 3X8 CanadaJ. D. Ringe, Klinikum Leverkusen Leverkusen GermanyL. -G. Ste-Marie, Université de Montréal Centre de Recherche du CH...

top  

  The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study

In conclusion risedronate could improve osteoporosis by increasing osteoprotegerin and reducing RANKL and IL-1β. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-009-0055-9Authors Umit Dundar, Afyon Kocatepe University Faculty of Medicine Department of Physical Medicine and Rehabilitation Mavi Hastane 03200 Afyonkarahisar TurkeyVural Kavuncu, Afyon Kocatepe University Faculty of Medicine Department of Physical Medicine and Rehabilitation Mavi Hastane 03200 Afyonkarahisar TurkeyIhsan H. Ciftci, Kocatepe University Faculty of Medicine Microbiology and Clinical Microbiology Afyonkarahisar TurkeyDeniz Evcik, Ufuk University Faculty of Medicine Physical Medicine and Rehabilitation Ankara TurkeyOzlem Solak, Afyon Kocatepe University Faculty of Medicine Department of...

top  

  Unusual mid-shaft fractures during long term bisphosphonate therapy.

Conclusion: Long-term bisphosphonate therapy may increase the risk of unusual long bone mid-shaft fractures. This is likely due to prolonged suppression of bone turnover, which could lead to accumulation of microdamage and development of hypermineralized bone. At present, the scope of this complication in the larger context of patients receiving bisphosphonate therapy is not known, but appears to be small. PMID: 19302584 [PubMed - as supplied by publisher] (Source: Clinical Endocrinology)

top  

  Prior treatment with vitamin K2 significantly improves the efficacy of risedronate

Conclusion  Prior treatment with MK-4 followed by risedronate significantly increased femur strength in comparison to the OVX controls. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0888-zAuthors Y. Matsumoto, Kanagawa Dental College Division of Radiology, Department of Maxillofacial Diagnostic Science 82 Inaokacho Yokosuka Kanagawa 238-8580 JapanY. Mikuni-Takagaki, Kanagawa Dental College Department of Functional Biology 82 Inaokacho Yokosuka 238-8580 Kanagawa JapanY. Kozai, Kanagawa Dental College Division of Radiology, Department of Maxillofacial Diagnostic Science 82 Inaokacho Yokosuka Kanagawa 238-8580 JapanK. Miyagawa, Kanagawa Dental College Department of Functional Biology 82 Inaokacho Yokosuka 238-8580 Kanagawa JapanK. Naruse, Kitas...

top  

  Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?

Discussion  Relative risk estimates from IPD analyses were the best choice for modelling fracture outcomes when applied in a specified high-risk population. In addition to superior statistical methodology, they utilized RCT cohorts that are more representative of higher risk patients requiring treatment (osteoporotic women ≥65 years with a prevalent vertebral fracture). Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0870-9Authors J. D. Adachi, St Joseph’s, Healthcare–McMaster University Department of Medicine 25 Charlton Avenue East, Suite 501 Hamilton Ontario L8N 1Y2 CanadaC. C. Kennedy, St Joseph’s, Healthcare–McMaster University Department of Medicine 25 Charlton Avenue East, Suite 501 Hamilton Ontario L8N 1Y2 CanadaA. Pap...

top  

  Comparative gastrointestinal safety of weekly oral bisphosphonates

Conclusions  We found no important difference in gastrointestinal safety between weekly oral bisphosphonates. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-009-0871-8Authors S. M. Cadarette, Brigham and Women’s Hospital, Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics Boston MA USAJ. N. Katz, Brigham and Women’s Hospital, Harvard Medical School Division of Rheumatology, Immunology and Allergy Boston MA USAM. A. Brookhart, Brigham and Women’s Hospital, Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics Boston MA USAT. Stürmer, Brigham and Women’s Hospital, Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics Boston MA USAM. R. Stedman, Brigham and Women’s...

top  

  [Breast Cancer] Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

Conclusion Risedronate did not prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer. (Source: Journal of Clinical Oncology)

top  

  Generalized arterial calcification of infancy: treatment with bisphosphonates.

Authors: Ramjan KA, Roscioli T, Rutsch F, Sillence D, Munns CF, Background A baby girl developed respiratory distress immediately after birth and required supplemental oxygen. She was born at term via lower-segment cesarean section. The parents were nonconsanguineous, and antenatal ultrasonography during the pregnancy at 18 and 32 weeks of gestation did not reveal any abnormalities. On examination at birth, no pulses were palpable; however, the baby's blood pressure was normal and no remarkable abnormalities were detected. Ultrasonography revealed widespread arterial calcification.Investigations Chest and abdominal radiography at birth and serial abdominal, renal and cardiac ultrasonography at follow-up examinations; dual-energy X-ray absorptiometry during treatment with bisphosphonat...

top  

  Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE).

Conclusions: In postmenopausal women at risk for fragility fracture receiving adjuvant anastrozole for BCA, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable affects in BMD over 24 months. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1137. (Source: Cancer Research)

top  

  Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance

Abstract  Analgesic effects of etidronate, alendronate and risedronate were compared in patients with osteoporosis and/or osteoarthritis by measuring the fall of skin impedance along with conventional subjective pain-estimation by visual rating scale (VRS). One hundred ninety-nine postmenopausal women consulting the Osteoporosis and Osteoarthritis Clinic of Katsuragi Hospital complaining of back and/or knee pain were randomly divided into four groups; Group A (49 subjects) given 5 mg/day alendronate, Group E (50 subjects) 200 mg/day etidronate, Group R (50 subjects) 2.5 mg/day risedronate and Group P no bisphosphonate. None of the four groups showed significant deviation from others as to age and parameters of bone metabolism. Proportions of subjects with ost...

top  

  Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.

Conclusions: Overall, in this study, the safety profiles of risedronate 100, 150, and 200 mg/mo were not different from that of risedronate 5 mg/d. Changes in efficacy measures in the monthly treatment groups were considered dose related and were not significantly different between the 5-mg/d group and the 150- and 200-mg/mo groups; similarity was greatest with 150 mg/mo. PMID: 19302900 [PubMed - in process] (Source: Clinical Therapeutics)

top  

  Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study

Abstract  Although osteoporosis in men is already a major public health problem, there is still a dearth of data about the effects of risedronate in male osteoporosis, especially in Japanese with primary osteoporosis. Therefore, the objective of our study was to investigate the effects of risedronate on bone mineral density (BMD), bone turnover, back pain, and fractures in these patients prospectively for two years (at baseline, three months, six months, twelve months, and twenty-four months) both longitudinally and compared with those of alfacalcidol. The subjects enrolled for this study were 66 Japanese male patients with untreated primary osteoporosis (mean age 63.52 ± 8.7 years), who were divided into two groups (44 with risedronate and 22 ...

top  

  LRP5 Polymorphisms and Response to Risedronate Treatment in Osteoporotic Men

In conclusion, the LRP5 A1330V polymorphism is associated with hip BMD in osteoporotic men, but allelic variations in LRP5 do not appear to be associated with response to bisphosphonate treatment. Content Type Journal ArticleDOI 10.1007/s00223-008-9207-5Authors Marcin Kruk, University of Edinburgh Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital Edinburgh EH4 2XU UKStuart H. Ralston, University of Edinburgh Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital Edinburgh EH4 2XU UKOmar M. E. Albagha, University of Edinburgh Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital Edinburgh EH4 2XU UK Journal Calcified Tissue InternationalOnline IS...

top  

  THe effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib

Abstract  We evaluated the effects of suppressed bone remodeling caused by bisphosphonate on microdamage accumulation and degree of mineralization of bone (DMB) for the dog rib in two independent studies. Study 1: 36 female beagles, 1-2 years old, were treated daily for 1 year with saline vehicle, risedronate at 0.5 mg/kg/day, or alendronate at 1.0 mg/kg/day. Study 2: 29 beagles, 1 year old, were given lactose, or incadronate at 0.3 mg/kg/day or 0.6 mg/kg/day for 3 years. In both studies, the ninth rib was harvested. Intracortical remodeling was significantly suppressed following either 1 year or 3 years of bisphosphonate treatment without impairment of primary mineralization, although the remodeling rate was obviously lower in study 2 than in study 1 because of the aging o...

top  

  Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study.

Authors: Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL The eValuation of IBandronate Efficacy (VIBE) head-to-head database fracture study compared fracture rates between patients treated with monthly ibandronate and weekly oral bisphosphonates (BPs). This large study included women >/=45 years old, newly prescribed monthly oral ibandronate or weekly oral alendronate or risedronate, and without malignancy or Paget's disease of bone. The primary analysis included patients who were adherent to treatment during the first 90 days after the index date. The risks of hip, nonvertebral, vertebral and any clinical fracture were compared using Cox proportional hazards models and adjusted for potential confounding factors. A secondary, "intent-to-treat" anal...

top  

  Small cancer risk reported with bone-strengthening drugs

The FDA mentions a few dozen cases of esophageal cancer in patients who took Fosamax, Actonel or Boniva. And a dentist sees a high incidence of osteonecrosis of the jaw. The family of bone-strengthening drugs called bisphosphonates -- best known by the brand names Fosamax, Actonel and Boniva -- pose a small risk of causing esophageal cancer, a Food and Drug Administration official reported Thursday in a letter to the New England Journal of Medicine. (Source: Los Angeles Times - Science)

top  

  Risedronate Doesn't Prevent Bone Loss During Chemotherapy

Although risedronate prevents bone loss in postmenopausal women, the agent does not appear to benefit premenopausal women being treated with chemotherapy for primary breast cancer, researchers report in an advance on-line issue of the Journal of Clinical Oncology. Reuters Health Information (Source: Medscape Med Students Headlines)

top  

  Effects of Short-Term Risedronate on Bone Resorption and Patient Satisfaction in Postmenopausal Osteoporosis Patients

Abstract: This multicenter, open-label study evaluated the effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal women with osteoporosis in Brazil. Entry requirements included: osteoporosis of the spine/femoral neck diagnosed by a bone mineral density (BMD) T-score≤−2.5 or radiographic fragility fracture within the last year and no treatment with osteoporosis medication in the preceding 3mo. Patients were treated with once weekly risedronate of 35mg for 12wk. Patients also received 1000mg calcium carbonate and 400IU vitamin D. The main outcome was the effect on bone resorption, as assessed by the quantification of serum C-telopeptide of type I collagen (CTX). Of the 556 women screened, 480 women received ≥1 dose of study drug (intent-to-treat...

top  

  Monthly risedronate (actonel) for postmenopausal osteoporosis.

Authors: PMID: 19104380 [PubMed - in process] (Source: Obstetrics and Gynecology)

top  

  Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study

Conclusion  Compared to compliant women, noncompliant women incurred significantly higher physician care and hospital care costs. Due to lower drug costs, total direct health care costs were lower among noncompliant women. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0818-5Authors J. Blouin, University of Montreal Faculty of Pharmacy PO Box 6128 Centre-Ville Station Montreal Quebec Canada H3C 3J7A. Dragomir, University of Montreal Faculty of Pharmacy PO Box 6128 Centre-Ville Station Montreal Quebec Canada H3C 3J7M. Fredette, HEC Montreal Department of Management Sciences Montreal CanadaL.-G. Ste-Marie, University of Montreal Faculty of Medicine Montreal Quebec CanadaJ. C. Fernandes, University of Montreal Faculty of Medicine Montreal Quebe...

top  

  Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.

Authors: Zikan V, Stepan JJ The aim of this study was to assess the effects of the antiresorptive treatments of alendronate (ALN), risedronate (RIS) and raloxifene (RLX) on the response of bone to endogenous parathyroid hormone (PTH) induced by acute hypocalcemia. Forty women (age, 55-80 years) with postmenopausal osteoporosis (treated with ALN, RIS and RLX or untreated-control group) were given infusions of sodium ethylenediaminetetraacetic acid (EDTA; 10 mg/kg of body weight). Serum ionized calcium (iCa), plasma intact PTH and marker of bone resorption, serum beta C-terminal telopeptide of type I collagen (beta-CTX; beta CrossLaps) were followed for 180 min. In all women, decrease in serum iCa following the EDTA load resulted in an acute increase in serum PTH. Between 60 and 180 min,...

top  

  Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis.

We present a study demonstrating nitrogen-containing bisphosphonates (N-BPs) to be capable of inhibiting Cryptosporidium parvum at low micromolar concentrations in infected MDCK cells. Predictably, the mechanism of action is based on inhibition of biosynthesis of isoprenoids but the target enzyme is unexpectedly a distinctive C. parvum enzyme dubbed nonspecific polyprenyl pyrophosphate synthase (CpNPPPS). This enzyme produces various isoprenoid products larger than FPP and is inhibited by N-BPs at subnanomolar concentrations. It is part of an isoprenoid pathway in Cryptosporidium distinctly different from other organisms. The proposed mechanism of action is corroborated by crystal structures of the enzyme with risedronate and zoledronate bound showing how this enzyme's unique chain length ...

top  

  The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates

Conclusion: Improvements in treatment persistence and compliance may improve the impact of bisphosphonates in reducing the risk of fractures. Yearly administration may also improve the impact on fracture risk reduction, unless long-term persistence is substantially reduced. (Source: QJM)

top  

  Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system

Conclusion: In the benefit/risk ratio, the use of chondroitin sulfate, diacereine, glucosamine sulfate, avocado/soybean unsaponifiables and hyaluronic acid could be of potential interest for the symptomatic management of OA. (Source: BMC Musculoskeletal Disorders)

top  

  Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence.

DISCUSSION: This review reinforces the irony that the least evidence is available for fragility fracture reduction in the group at greatest risk; the old old and those with non vertebral and hip fracture. Although there is good evidence for the benefit of the bisphosphonates (Alendronate and Risedronate), Teriparatide and Strontium Ranelate in vertebral fracture reduction, there are very limited data for non vertebral and hip fracture reduction. Strontium Ranelate is the only agent to date that has demonstrated a reduction in non vertebral and hip fracture events in this high risk elderly female population. Perhaps we need to adopt different strategies in managing older patients with osteoporosis as their fracture risks and treatment strategies may be quite different from younger populatio...

top  

  ACTONEL WITH CALCIUM (Risedronate Sodium And Calcium Carbonate) Kit [Procter And Gamble Pharmaceuticals, Inc.]

Updated Date: Dec 9, 2008 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

top  

  Bisphosphonates: What is the Latest Protocol?

I have read several articles and comments on Bisphosphonates, as it relates to dental implants, but this whole matter keeps developing and changing. What is the current protocol for managing dental implant patients taking Actonel? >>Read More and Comment (Source: Dental Implants Discussed by Experts)

top  

  Early Teriparatide Response May Hinge on Prior Bisphosphonate Therapy

In postmenopausal women with osteoporosis, prior treatment with risedronate does not impair early responsiveness to teriparatide to the same extent as prior treatment with alendronate, a study suggests. Reuters Health Information (Source: Medscape Diabetes Headlines)

top  

  Fluorescently Labeled Risedronate and Related Analogues: “Magic Linker” Synthesis

Bioconjugate Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). <br/> (Source: Bioconjugate Chemistry)

top  

  Differences in persistence among different weekly oral bisphosphonate medications

Conclusion  This study provides further evidence of poor persistence to newly initiated oral weekly BP therapies, particularly for the patients started on generic alendronate. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0795-8Authors O. Sheehy, Centre Hospitalier de l’Université de Montréal (CHUM) Pharmacoepidemiology and Pharmacoeconomics Research Unit 3850 Saint-Urbain, Pavillon Masson Montreal QC H2W 1T7 CanadaC. M. Kindundu, Novartis Pharmaceuticals Canada Montreal QC CanadaM. Barbeau, Novartis Pharmaceuticals Canada Montreal QC CanadaJ. LeLorier, Centre Hospitalier de l’Université de Montréal (CHUM) Pharmacoepidemiology and Pharmacoeconomics Research Unit 3850 Saint-Urbain, Pavillon Masson Montreal QC H2W 1T7 Canada Jo...

top  

  Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis

In conclusion, BMD increase at the lumbar spine by bisphosphonate treatment was not related to any pretreatment parameters, including body size, body composition, and bone/mineral metabolism in postmenopausal Japanese women with primary osteoporosis, although FPG correlated partly to BMD through lean body mass. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00774-008-0005-yAuthors Hiroshi Kaji, Kobe University Graduate School of Medicine Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine 7-5-2 Kusunoki-cho, Chuo-ku Kobe 650-0017 JapanItoko Hisa, Kobe University Graduate School of Medicine Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine 7-5-2 Kusunoki-cho, Chuo-ku Kobe 650-0017 JapanYoshifumi Inou...

top  

  Update on Early Communication: Bisphosphonates marketed as Alendronate (Fosamax, Fosamax Plus D); Etidronate (Didronel); Ibandronate (Boniva); Pamidronate (Aredia); Risedronate (Actonel, Actonel W/Calcium); Tiludronate (Skelid); Zoledronic acid (Reclast, Zometa)

Early Communication about the FDA's review of safety data showed no clear association between overall bisphosphonate exposure and the rate of serious or non-serious atrial fibrillation (Source: FDA MedWatch)

top  

  Update on Early Communication: Bisphosphonates marketed as Alendronate (Fosamax, Fosamax Plus D); Etidronate (Didronel); Ibandronate (Boniva); Pamidronate (Aredia); Risedronate (Actonel, Actonel W/Calcium); Tiludronate (Skelid); Zoledronic acid (Reclast, Zometa)

Audience: Geriatricians, gynecologists, orthopedic surgeons, other healthcare professionals[Posted 11/12/2008] FDA issued an update to the Agency's review of safety data regarding the potential increased risk of atrial fibrillation in patients... (Source: Drugs.com - FDA MedWatch Alerts)

top  

  Update on Early Communication: Bisphosphonates marketed as Alendronate (Fosamax, Fosamax Plus D); Etidronate (Didronel); Ibandronate (Boniva); Pamidronate (Aredia); Risedronate (Actonel, Actonel W/Calcium); Tiludronate (Skelid); Zoledronic acid (Reclast, Zometa)

Audience: Geriatricians, gynecologists, orthopedic surgeons, other healthcare professionals[Posted 11/12/2008] FDA issued an update to the Agency's review of safety data regarding the potential increased risk of atrial fibrillation in patients... (Source: Drugs.com - FDA MedWatch Alerts)

top  

  Compatibility of risedronate sodium tablets with food thickeners.

CONCLUSION: Risedronate sodium tablets were compatible for 24 hours with five food thickeners. PMID: 18997142 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)

top  

  Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease

Abstract  Bisphosphonates decrease bone resorption and reduce significantly the rate of skeletal complications in patients with metastatic bone disease. Bisphosphonates have also been shown to exhibit antitumor activity in vitro but in vivo results have been equivocal. In the present study, we investigated the effects of bisphosphonate treatment alone or in combination with the cytostatic docetaxel on the growth of breast cancer cells in bone. Tumor gowth was studied in an athymic nude mice model inoculated with MDA-231-B/luc+ breast cancer cells. Two days after the inoculation, mice were treated with risedronate, zolendronate or docetaxel alone or with a combination of risedronate and docetaxel. Bone destruction and tumor growth were evaluated radiographically, histologica...

top  

  Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition In vivo

In conclusion, our study shows that decreasing the bone mineral affinity of bisphosphonates is an effective therapeutic strategy to inhibit skeletal tumor growth in vivo. [Cancer Res 2008;68(21):8945–53] (Source: Cancer Research)

top  

  Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization

This study was undertaken to determine how PTH and risedronate alter bone quality following glucocorticoid excess.Five-month-old male Swiss-Webster mice were treated with the glucocorticoid prednisolone (5 mg/kg in a 60-day slow-release pellet) or placebo. From day 28 to day 56, 2 groups of glucocorticoid-treated animals received either PTH (5 [mu]g/kg) or risedronate (5 [mu]g/kg) 5 times per week. Bone quality and quantity were measured using x-ray tomography for the degree of bone mineralization, microfocal computed tomography for bone microarchitecture, compression testing for trabecular bone strength, and biochemistry and histomorphometry for bone turnover. In addition, real-time polymerase chain reaction (PCR) and immunohistochemistry were performed to monitor the expression of severa...

top  

  RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction

Conclusions  The absolute rate of clinical fractures among alendronate and risedronate users was similar both at 1 year and beyond, suggesting comparable effectiveness between agents. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0772-2Authors J. R. Curtis, University of Alabama at Birmingham Center for Education and Research on Therapeutics (CERTs) Birmingham AL USAA. O. Westfall, University of Alabama at Birmingham Department of Biostatistics Birmingham AL USAH. Cheng, University of Alabama at Birmingham Center for Education and Research on Therapeutics (CERTs) Birmingham AL USAK. G. Saag, University of Alabama at Birmingham Center for Education and Research on Therapeutics (CERTs) Birmingham AL USAE. Delzell, University of Alabama a...

top  

  Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates

This article summarizes the most currently available data relative to nonvertebral and hip fracture risk reduction for the N-containing bisphosphonates alendronate, ibandronate, risedronate, and zoledronic acid, and presents results of an analysis of comparative efficacy of these compounds using the technique of adjusted indirect comparisons. Content Type Journal ArticleDOI 10.1007/s11914-008-0016-6Authors Marc C. Hochberg, University of Maryland School of Medicine 10 South Pine Street, MSTF 8-34 Baltimore MD 21201 USA Journal Current Osteoporosis ReportsOnline ISSN 1544-2241Print ISSN 1544-1873 Journal Volume Volume 6 Journal Issue Volume 6, Number 3 / September, 2008 (Source: Current Osteoporosis Reports)

top  

  Effect of risedronate in a minipig cartilage defect model with allograft

Cartilage/chondrocyte transplantation is frequently utilized in the repair of focal chondral defects. It has been proposed that failure of subchondral bone maintenance or restoration is a factor contributing to the failure of cartilage-forming transplants. Some studies reveal that the transplant is associated with subchondral bone resorption, often leading to deep pits beneath the presumptive cartilage repair site. Thus, the question is raised as to the utility of agents, such as bisphosphonates, to inhibit bone remodeling at the transplant site. In the present study we show that oral administration (three times weekly) of the bisphosphonate, risedronate, inhibited the subchondral bone loss deep to the cultured allogeneic graft tissue site in attempted repair of surgically created chondral...

top  

  Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate

Conclusion  High doses of bisphosphonates result in the accumulation of AGEs and a reduction in energy absorption of cortical bone. The increased accumulation of AGEs in these tissues may help explain altered bone matrix quality due to the administration of BPs in animal models. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0754-4Authors S. Y. Tang, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute Department of Biomedical Engineering Troy NY USAM. R. Allen, Indiana University-Purdue University Indianapolis Department of Anatomy and Cell Biology Indianapolis IN USAR. Phipps, Procter and Gamble Pharmaceuticals, Inc. Mason OH USAD. B. Burr, Indiana University-Purdue University Indianapolis Department of...

top  

  Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment

Conclusions  The results suggested that long-term treatment with bisphosphonates necessitates careful follow-up of the patients. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00776-008-1265-zAuthors Kousuke Iba, Sapporo Medical University School of Medicine Department of Orthopaedic Surgery South-1, West-16, Chuo-ku Sapporo 060-8543 JapanJunichi Takada, Chitose City Hospital Orthopaedic Surgery Chitose JapanNaoko Hatakeyama, Sapporo Medical University School of Medicine Department of Orthopaedic Surgery South-1, West-16, Chuo-ku Sapporo 060-8543 JapanYasuhiro Ozasa, Sapporo Medical University School of Medicine Department of Orthopaedic Surgery South-1, West-16, Chuo-ku Sapporo 060-8543 JapanTakuro Wada, Sapporo Medical University School of Medicine D...

top  

  DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass

Conclusions  HSA offers insight into the potential mechanisms of fracture risk reduction from pharmacologic intervention. In the current study, treatment with once-weekly bisphosphonates resulted in significant improvements in hip geometric parameters. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00198-008-0762-4Authors S. L. Bonnick, Clinical Research Center of North Texas 2921 Country Club Road, Ste. 101 Denton TX 76210 USAT. J. Beck, Johns Hopkins University Baltimore MD USAF. Cosman, Helen Hayes Hospital Clinical Research Center West Haverstraw NY USAM. C. Hochberg, University of Maryland School of Medicine Baltimore MD USAH. Wang, Merck & Co., Inc. Merck Research Laboratories Rahway NJ USAA. E. de Papp, Merck & Co., Inc. Merck Research Laborato...

top  

  Low Incidence of Anti-Osteoporosis Treatment After Hip Fracture

Conclusions: The vast majority of patients who experience a hip fracture do not take anti-osteoporotic therapy after the fracture. Furthermore, among patients who begin alendronate treatment after the fracture, the adherence to treatment decreases over time and remains suboptimal. (Source: JBJS [Am])

top  

  Low incidence of anti-osteoporosis treatment after hip fracture.

CONCLUSIONS: The vast majority of patients who experience a hip fracture do not take anti-osteoporotic therapy after the fracture. Furthermore, among patients who begin alendronate treatment after the fracture, the adherence to treatment decreases over time and remains suboptimal. PMID: 18829912 [PubMed - in process] (Source: The Journal of Bone and Joint Surgery. American volume)

top  

  Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective.

Authors: Boonen S, Dejaeger E, Vanderschueren D, Venken K, Bogaerts A, Verschueren S, Milisen K Age is a major determinant of osteoporosis, but the elderly are rarely assessed and often remain untreated for this condition. Falls, co-morbidities and co-medications compound the risk of fracture in senile osteoporosis. The prevalence of osteoporosis is expected to increase with increasing life expectancy, and the associated fractures - particularly hip fractures - will lead to significant demands on health resources. Treatment of senile osteoporosis can include pharmacological and non-pharmacological intervention. Calcium and vitamin D dietary supplementation is a relatively low-cost way of reducing the risk of fracture. Pharmacological interventions with risedronate, zoledronic acid, or ...

top  

  Monthly Ibandronate as Effective as Weekly Risedronate or Alendronate

Monthly therapy is associated with fracture rates similar to weekly therapy in several patient types. Medscape Medical News (Source: Medscape Medical News Headlines)

top  

  Self-reported compliance with osteoporosis medication-Qualitative aspects and correlates.

CONCLUSION: Compliance with osteoporosis medication in Czech women is suboptimal, in particular the prevalence of co-medication with calcium/vitamin D should be higher. It is needed to implement strategies focused on the patient's beliefs about the disease and perceptions of outcome rather than those promoting the knowledge alone. PMID: 18774663 [PubMed - as supplied by publisher] (Source: Maturitas)

top  

Top Viagra Store

A first shop in the series of one-pill shops is rightfully viagra-targeted. The index page offers only Viagra, both generic and original.It is possible to purchase other ED products from other pagers, but the main accent is on Viagra.

top-viagra-store.com

Indian Meds

A most recent indian-themed, ethnic site. Includes generic and original (brand) products. al our standard navigational tools and support options are available. This site converts nicely on general pharmaceutical traffic as it has products for vurtually any need.

indianmeds.org

Friendly ED Pharmacy

Many ED customers are anxious about the status their orders. This special friendly site is here to solve the problem. "State of the art" design features high usability and clearly visible support options. All this helps to satisfy even the most demanding customer and results in increased sales ratio.

friendly-ed-pharmacy.com

Popular ED Products

This ED site offers simplistic design that gets right to the point - this IS the site for ED. Popular ED list the top selling products and converts best on ED-targeted, pill-specific traffic.

popular-ed-products.com

Perfect ED Store

This site is just right for ED customers. All ED products are conveniently listed at main page, allowing to make an easy choice. Our regular Sample Pills Offer is emphasized here. Customers can try new products and are likely to return for more refills.

perfect-ed-store.com

Worlds Best Pharmacy

The name says it all. This is the best online pharmacy on the web. The index page is set to show the most polular ED products, while the menu and quicksearch allow to find products in other categories.

worlds-best-pharmacy.com

Delhi Drugs

This Indian-themed site offers a completely new design. All our generic products are availabe and can easily be located with the help of quicksearch feature. Includes our latest shopping engine and billing page.

www.delhi-drugs.com

Indian Generics

Many customers are looking for Indian drugs, and this site is designed specifically for such customers. It includes many generic products, modern design, translated into 7 languages and prices in both USD and Euros. Also it uses our latest shopping engine and billing page.

www.indian-generics.com